When Transfer Pricing Reviews Open Excise Doors: The Hidden Duty Exposure in US-India R&D Arrangements

The Audit That Arrives Wearing Two Hats

When an Indian transfer pricing audit notice lands on a US company's desk, the immediate instinct is to route it to the international tax team and begin assembling comparables analysis, benchmarking studies, and intercompany agreement documentation. That response is appropriate as far as it goes. What it frequently misses is that the transfer pricing examiner is often not the only authority reviewing the transaction.

Indian revenue authorities have increasingly coordinated transfer pricing inquiries with indirect tax and customs examinations in ways that US companies, accustomed to more siloed regulatory structures, do not anticipate. A transfer pricing audit focused on an R&D cost-sharing arrangement between a US parent and its Indian subsidiary may simultaneously generate questions about whether component transfers within that arrangement were correctly classified for excise or GST purposes, whether the service fee structure created a taxable supply that was underreported, and whether the valuation methodology used for transfer pricing purposes is consistent with the transaction value declared for duty assessment.

For R&D-intensive US companies — pharmaceutical firms, technology manufacturers, defense contractors, and industrial equipment companies among them — this convergence represents a category of risk that neither their transfer pricing documentation nor their excise compliance programs were designed to address together.

Why R&D Arrangements Are Particularly Vulnerable

Not all intercompany transactions carry equal exposure at the transfer pricing–excise intersection. R&D arrangements are disproportionately vulnerable for reasons that are worth examining in some detail.

First, R&D cost-sharing agreements frequently involve the transfer of partially developed intellectual property, prototype components, and proprietary materials between group entities. Each of these transfers has a potential excise or customs classification consequence that is distinct from its transfer pricing characterization. A component transferred at a cost-sharing price calibrated to reflect the arm's length contribution of each entity may nonetheless require independent customs valuation under India's Customs Valuation Rules — and the two numbers are not required to be the same. When they diverge materially, that divergence attracts scrutiny.

Second, R&D service arrangements — where a US parent pays an Indian subsidiary to conduct research on its behalf, or vice versa — involve service fee structures that Indian authorities increasingly examine for GST reverse charge implications and for consistency with the arm's length standard simultaneously. If the fee is set at a level that a transfer pricing examiner considers artificially low, the same fee may prompt a GST valuation challenge on the grounds that the declared service value understates the actual consideration exchanged.

Third, the technical complexity of R&D transactions makes them difficult to document in ways that satisfy both the transfer pricing standard and the indirect tax classification standard at the same time. Transfer pricing documentation is designed to justify a price; excise and customs documentation is designed to justify a classification and a valuation. These are related but distinct exercises, and companies that prepare only the former leave the latter entirely exposed.

Real Audit Patterns US Companies Should Recognize

Indian revenue authorities have developed specific inquiry techniques for surfacing excise and duty exposure through transfer pricing reviews. US companies with existing or anticipated R&D arrangements should recognize these patterns.

The comparability challenge as a classification probe. Transfer pricing examiners will frequently challenge the comparability of the transactions a US company has used to benchmark its R&D arrangement. In doing so, they often surface information about how comparable transactions were classified for excise or customs purposes — and then ask why the company's own classification differs. What begins as a pricing debate becomes a classification dispute without the company fully recognizing the transition.

The valuation consistency test. Indian authorities will compare the transaction values declared in transfer pricing documentation against the values declared in customs or excise filings for the same goods or services. Inconsistencies between these two sets of declared values — which arise routinely when they are prepared by different advisors without coordination — are treated as evidence of either transfer pricing manipulation or duty undervaluation, or both.

The embedded royalty argument. In R&D arrangements where a US parent contributes technology or IP to an Indian subsidiary's research activities, Indian authorities have argued that the contribution constitutes a royalty-bearing license and that the royalty should have been included in the customs value of any goods imported in connection with that arrangement. This argument has been applied with particular force against US pharmaceutical and technology companies with active Indian R&D centers.

The Documentation Gap That Auditors Exploit

The fundamental vulnerability in most US companies' positions is not that their transfer pricing is incorrect or that their excise classifications are wrong — it is that the two sets of documentation were prepared independently, by different advisors, using different analytical frameworks, and have never been reconciled against each other.

A transfer pricing study prepared by a Big Four firm and an excise classification memo prepared by an Indian indirect tax specialist may each be technically defensible on its own terms while being mutually inconsistent in ways that become apparent only when an auditor places them side by side. The auditor's job, at that point, is simply to identify the inconsistency and ask the company to explain it. Companies that have never performed that reconciliation themselves have no prepared answer.

This documentation gap is particularly pronounced for US companies that manage their Indian transfer pricing from their corporate tax department in the United States while delegating excise and GST compliance to a local team in India. The two groups operate on different reporting lines, communicate infrequently, and rarely review each other's work product. The result is a structural blind spot that is invisible from either vantage point individually.

Building a Defensive Documentation Architecture

Addressing this exposure requires a deliberate effort to treat transfer pricing and indirect tax documentation as components of a single integrated compliance posture rather than as separate workstreams.

Unified transaction mapping is the essential starting point. Every intercompany R&D transaction — cost-sharing payments, component transfers, prototype shipments, service fees, IP licenses — should be mapped in a single document that identifies both the transfer pricing characterization and the indirect tax classification for each item. This map does not need to resolve every ambiguity, but it must make the relationship between the two frameworks explicit and demonstrate that the company has considered them together.

Cross-framework consistency review should be conducted before any transfer pricing study is finalized. The values, characterizations, and comparability conclusions in the transfer pricing documentation should be reviewed by the indirect tax team — and vice versa — to identify points of potential inconsistency before those inconsistencies are discovered externally.

Proactive customs valuation analysis for component transfers within R&D arrangements is an area where US companies consistently underinvest. The arm's length price is not automatically the correct customs value under Indian law, and the gap between the two requires specific documentation under the Customs Valuation Rules. Companies that address this gap proactively are in a substantially stronger position than those who address it for the first time in response to an audit notice.

Audit response protocol integration means ensuring that when a transfer pricing inquiry arrives, the indirect tax compliance team is notified immediately and the two groups coordinate their responses. An answer given to a transfer pricing examiner about how an R&D arrangement is structured can have direct consequences for indirect tax exposure, and those consequences are best managed in real time rather than after the fact.

The Compounding Cost of Siloed Compliance

For US companies with substantial Indian R&D operations, the transfer pricing–excise intersection is not a theoretical concern — it is an active audit risk that Indian revenue authorities are increasingly equipped and motivated to pursue. The companies that navigate it most successfully will be those that recognize the convergence early, invest in integrated documentation before an inquiry begins, and refuse to treat indirect tax compliance as a problem entirely separate from their international tax posture.

At RajExcise Advisors, we have observed that the cost of closing this documentation gap proactively is a fraction of the cost of addressing it reactively. The audit that arrives wearing two hats is best met by a defense that was designed to address both.